HC Wainwright & Co. Assumes Larimar Therapeutics at Buy, Announces Price Target of $10
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Larimar Therapeutics (NASDAQ: LRMR ) with a Buy rating and announces Price Target of $10.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.